PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients

• Main Authors: Stefan Willmann (Author), Eleonora Marostica (Author), Nelleke Snelder (Author), Alexander Solms (Author), Markus Jensen (Author), Maximilian Lobmeyer (Author), Anthonie W. A. Lensing (Author), Claudette Bethune (Author), Erin Morgan (Author), Rosie Z. Yu (Author), Yanfeng Wang (Author), Shiangtung W. Jung (Author), Richard Geary (Author), Sanjay Bhanot (Author)
• Format: Book
• Published: Wiley, 2021-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract IONIS‐FXIRX (BAY2306001) is an antisense oligonucleotide that inhibits the synthesis of coagulation factor XI (FXI) and has been investigated in healthy volunteers and patients with end‐stage renal disease (ESRD). FXI‐LICA (BAY2976217) shares the same RNA sequence as IONIS‐FXIRX but contain...